Application of nutmeg five-flavor pill in preparation of medicine for relieving cardiotoxicity related to anthracycline chemotherapeutic tumor molecule targeted medicine

By using the composition of Bogume Wuwei Pills, the cardiotoxicity and intestinal disorder caused by anthracycline chemotherapy drugs were solved, the heart and intestinal health was significantly improved, and a safe medication plan for breast cancer patients was provided.

CN118948938AActive Publication Date: 2024-11-15CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411069364.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-06
Publication Date
2024-11-15
Estimated Expiration
2044-08-06

AI Technical Summary

Technical Problem

Severe cardiotoxicity and intestinal microbial disorders caused by anthracycline chemotherapy drugs such as doxorubicin and trastuzumab in breast cancer treatment, and the lack of effective cardioprotective agents and bacterial balance recovery programs hinders clinical safety Use medicine.

Method used

Bolognese Wuwei Pills are made of nutmeg, Tumuxiang, Muxiang, Guangjujube and cypress. Excipients are provided through oral form to increase the ejaculation fraction of left ventricular, reduce cardiac tissue pathological damage and intestinal microbial disorders, and regulate Tryptophan metabolite levels improve heart and intestinal health.

Benefits of technology

Significantly improve the cardiotoxicity of doxorubicin/trastuzumab-related, restore intestinal flora balance, reduce cardiac pathological damage and metabolic disorders, and improve the survival rate and quality of life of breast cancer patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948938A_ABST
    Figure CN118948938A_ABST
Patent Text Reader

Abstract

The invention provides an anthracycline chemotherapeutic drug tumor molecular targeting drug, and the meat and nutmeg five-flavor pill has a remarkable improvement effect on doxorubicin / trastuzumab related cardiotoxicity, and can restore intestinal flora balance and improve intestinal metabolism.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of medicine. Specifically, the present application provides the use of Roukou Wuwei Pills in the preparation of a drug for alleviating the cardiac toxicity associated with anthracycline chemotherapy drugs and tumor molecular targeted drugs. Background Art

[0002] According to the latest data, the number of new cases of breast cancer in the world in 2022 is close to 2.3 million, and the number of deaths is about 670,000, ranking first in both incidence and mortality among female tumors; according to the latest statistics from the National Cancer Center in 2022, the number of new cases of breast cancer in China is 357,200, second only to lung cancer among female cancers, accounting for 15.6%. Among them, about 20-30% of breast cancer patients have overexpression of HER2, which is usually associated with poor prognosis. Anthracyclines are the cornerstone drugs for adjuvant chemotherapy for breast cancer and can significantly improve the survival of breast cancer patients. Trastuzumab is the first humanized monoclonal antibody targeting HER2 and is the first-line treatment for HER2-positive recurrent metastatic breast cancer. Many studies have shown that the addition of trastuzumab to adjuvant chemotherapy can greatly improve the disease-free survival and overall survival rate of breast cancer patients.

[0003] However, both anthracyclines and trastuzumab can cause severe cardiotoxicity. Several large-scale clinical studies have shown that when the two drugs are used in combination or sequentially, the incidence of cardiovascular toxicity is further increased, up to 25%. At present, anti-tumor drug-related cardiotoxicity has become an important problem that hinders the safe use of drugs in clinical practice. In terms of treatment, only dexrazoxane alone is a cardioprotective agent approved by the US Food and Drug Administration, but its clinical use is limited due to the emergence of secondary malignancies and myelodysplastic syndrome. Therefore, finding more effective cardioprotective agents is of great significance for the safe use of anti-tumor drugs.

[0004] Roukou Wuwei Pills, from the "Mongol Medical Formula Collection", are included in the "Pharmaceutical Standards of the Ministry of Health of the People's Republic of China: Mongolian Medicine". It is composed of five medicinal materials: nutmeg, scutellaria baicalensis, costusroot, jujube and longan. Studies have shown that nutmeg has anti-arrhythmic and antioxidant effects, and jujube has the effects of clearing heart heat, strengthening the heart, and calming the heart, etc., and has a good effect on heart diseases such as heart stabbing and palpitations. According to the 2020 edition of the "Pharmacopoeia of the People's Republic of China", jujube can promote qi and blood circulation, nourish the heart and calm the mind, and can be used to treat clinical symptoms of ischemic heart disease (IHD). Many studies have shown that Roukou Wuwei Pills play an important role in the treatment of various heart diseases, such as it can be used to treat arrhythmias and has a protective effect on myocardial infarction. However, there are currently no studies on the effectiveness of Roukou Wuwei Pills in anthracycline chemotherapy drugs / tumor molecular targeted drugs-related cardiotoxicity.

[0005] Therefore, the development of the uses of Roukou Wuwei Pills can not only add new indications and broaden its applications, but also help improve the quality of medical care and has broad market prospects. Summary of the invention

[0006] On the one hand, the present application provides the use of Roukou Wuwei Pills in the preparation of a drug for reducing the cardiac toxicity associated with anthracycline chemotherapy drugs and tumor molecular targeted drugs.

[0007] Furthermore, the anthracycline chemotherapy tumor molecular targeted drugs are doxorubicin and trastuzumab.

[0008] Furthermore, the cardiac toxicity includes decreased left ventricular ejection fraction and left ventricular shortening fraction, increased left ventricular end-systolic volume and left ventricular end-systolic diameter, increased serum cTnI and BNP levels, and cardiac tissue pathological damage.

[0009] Furthermore, the drug has one or more of the following functions:

[0010] (1) Increase left ventricular ejection fraction and left ventricular fractional shortening;

[0011] (2) decreased left ventricular end-systolic volume and increased left ventricular end-systolic diameter;

[0012] (4) Reduce serum cTnI and BNP levels;

[0013] (3) Improve cardiac tissue pathological damage.

[0014] On the one hand, the present application provides the use of Roukou Wuwei Pills in the preparation of a drug for alleviating intestinal microbial imbalance caused by anthracycline chemotherapy drugs and tumor molecular targeted drugs.

[0015] Furthermore, the anthracycline chemotherapy tumor molecular targeted drugs are doxorubicin and trastuzumab.

[0016] Furthermore, the intestinal microbial imbalance includes an increase in the abundance of Firmicutes and Actinobacteria; a decrease in the abundance of Lactobacillaceae, Lachnospiraceae, norank_o_Clostridia_UCG-014, and Prevotellaceae; an increase in the abundance of Bifidobacteriaceae and Clostridiumaceae; an increase in the abundance of norank_f_Muribaculaceae, Bifidobacterium, Clostridium_sensu_stricto_1, and Faecalibacterium; and a decrease in the abundance of orank_f_norank_o_Clostridia_UCG-014, norank_f_norank_o_RF39, and Lachnospiraceae_NK4A136_group.

[0017] Furthermore, the drug has one or more of the following functions:

[0018] (1) Reduce the abundance of Firmicutes and Actinobacteria;

[0019] (2) increased abundance of Lactobacillusaceae, Lachnospiraceae, norank_o_Clostridia_UCG-014, and Prevotellaceae in rats;

[0020] (3) reduce the abundance of Bifidobacteriaceae and Clostridiaceae;

[0021] (4) reduced abundance of norank_f_Muribaculaceae, Bifidobacterium, Clostridium_sensu_stricto_1, and Faecalibacterium;

[0022] (5) The abundance of norank_f_norank_o_Clostridia_UCG-014, norank_f_norank_o_RF39, and Lachnospiraceae_NK4A136_group increased.

[0023] On the one hand, the present application provides the use of Roukou Wuwei Pills in the preparation of a drug for alleviating metabolic disorders caused by anthracycline chemotherapy drugs and tumor molecular targeted drugs.

[0024] Furthermore, the anthracycline chemotherapy tumor molecular targeted drugs are doxorubicin and trastuzumab.

[0025] Further, the drug regulates the level of tryptophan metabolites.

[0026] Furthermore, the drug is for oral administration.

[0027] Furthermore, the medicine includes pharmaceutically acceptable excipients.

[0028] The nutmeg and five-flavor pills described in the present application are prepared from nutmeg, inulin, costusroot, jujube and piper longum. While complying with the common sense of Mongolian medicine and national standards, the ratio of ingredients and excipients may vary due to differences among manufacturers and understanding of the formula.

[0029] The technical solution of the present application is preferably used for breast cancer patients, and other anthracycline chemotherapy drugs and tumor molecular targeted drugs, such as doxorubicin and trastuzumab, can also be used.

[0030] Roukou Wuwei Pills are the core medicine for the treatment of "Heyi" in Mongolian medicine. They are used to treat heart "Heyi" disease, heart pain, delirium, syncope, palpitations, etc. Studies have found that Roukou Wuwei Pills also have a good improvement effect on doxorubicin / trastuzumab-related cardiotoxicity, and can restore the balance of intestinal flora and improve intestinal metabolism. It is especially effective for breast cancer patients with intestinal flora disorders after receiving sequential therapy with doxorubicin and trastuzumab.

[0031] The advantages of Roukou Wuwei Pill in improving doxorubicin / trastuzumab-related cardiotoxicity are as follows:

[0032] Roukou Wuwei Pills have a significant improvement effect on doxorubicin / trastuzumab-related cardiotoxicity, fully demonstrating the therapeutic advantages of the effective ingredients of traditional Chinese medicine and providing an effective strategy for preventing and treating cardiotoxicity associated with sequential therapy of doxorubicin and trastuzumab.

[0033] Regulatory effect of Roukou Wuwei Pills on intestinal flora: Sequential therapy with doxorubicin and trastuzumab disrupts the balance of intestinal flora, while Roukou Wuwei Pills has obvious advantages in improving the composition of beneficial flora in the body and restoring the balance of flora.

[0034] The regulatory effect of Roukou Wuwei Pills on the body's metabolism: Sequential therapy with doxorubicin and trastuzumab can disrupt the metabolic balance in the body, while Roukou Wuwei Pills has obvious advantages in improving the metabolic balance in the body. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 The changes in rat body weight during the administration period;

[0036] Figure 2A is the cTn I content in the plasma of rats in each group;

[0037] Figure 2B is the BNP content in the plasma of rats in each group;

[0038] Figure 3A is the left ventricular ejection fraction of rats in each group;

[0039] Figure 3B is the left ventricular short axis shortening rate of rats in each group;

[0040] Figure 3C is the left ventricular end-systolic volume of rats in each group;

[0041] Figure 3D is the left ventricular end-systolic diameter of rats in each group;

[0042] Figure 4A This is the M-mode echocardiogram of rats in the normal group;

[0043] Figure 4B This is the M-mode echocardiogram of rats in the normal group;

[0044] Figure 4C This is the M-mode echocardiogram of rats in the high-dose group of Roukou Wuwei Pills;

[0045] Figure 4D This is the M-mode echocardiogram of rats in the Roukou Wuwei Pill low-dose group;

[0046] Figure 5A HE staining results of the heart of rats in the normal group;

[0047] Figure 5B HE staining results of the heart of rats in the model group;

[0048] Figure 5C This is the HE staining result of the heart of rats in the low-dose Roukou Wuwei Pill group;

[0049] Fig. 6A This is the PCA graph under positive ion mode;

[0050] Figure 6B This is the PCA graph under negative ion mode;

[0051] Fig. 7A OPLS-DA graph of the normal group and the model group under positive ion mode;

[0052] Figure 7B OPLS-DA graph of the model group and Roukou Wuwei Pills group under positive ion mode;

[0053] Fig. 8A The volcano plot of the differential metabolites between the model group and the normal group;

[0054] Figure 8B The volcano plot of differential metabolites between the model group and the Roukou Wuwei Pills group;

[0055] Fig. 9 The Venn diagram of differential metabolites among the normal group, model group, and Roukou Wuwei Pills group (the left side is the model group vs. the normal group, and the right side is the Roukou Wuwei Pills group vs. the model group);

[0056] Fig.10 For KEGG pathway enrichment analysis;

[0057] Fig.11 for alpha diversity analysis;

[0058] Fig. 12A For A NMI)S analysis;

[0059] Fig. 12B It is PCoA principal coordinate analysis;

[0060] Fig.13A is the relative microbial abundance of each group at the phylum level;

[0061] Fig. 13B is the relative microbial abundance of each group at the family level;

[0062] Fig. 13C is the relative microbial abundance of each group at the genus level;

[0063] Fig.14A Analyze cladograms for LEfSe;

[0064] Fig. 14B Histogram for LEfSe analysis. DETAILED DESCRIPTION

[0065] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the art or the product instructions are used. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased through regular channels.

[0066] Experimental Example 1

[0067] In this example, Roukou Wuwei Pills were used for pharmacodynamic experiments to clarify their protective effect on doxorubicin / trastuzumab-induced cardiotoxicity. Roukou Wuwei Pills in the following experimental examples were purchased from Inner Mongolia Kulun Mongolian Medicine Co., Ltd., and their prescriptions mainly contained Chinese medicines such as nutmeg, inulin, costusroot, jujube, and longan.

[0068] Drugs and dosage

[0069] The cumulative dose of doxorubicin in the model group was 15 mg / kg, and the cumulative dose of trastuzumab was 20 mg / kg. The low-dose dose of Roukou Wuwei Pills was 0.81 mg / kg; the high-dose dose of Roukou Wuwei Pills was 1.62 mg / kg. The modeling doses of doxorubicin and trastuzumab were based on the references. The low-dose group of Roukou Wuwei Pills was equivalent to the clinical equivalent dose, and the high-dose group was equivalent to twice the clinical equivalent dose. Doxorubicin was administered by tail vein injection, and trastuzumab was administered by intraperitoneal injection. Roukou Wuwei Pills were suspended with sodium carboxymethylcellulose and administered by gavage.

[0070] animal

[0071] 8-week-old female SD rats, weighing 200±20 g.

[0072] Methods and Results

[0073] Animal Grouping

[0074] After one week of adaptive feeding, the rats' body weights were recorded and randomly divided into 4 groups, namely, control group, model group, Roukou Wuwei Pills low-dose group and Roukou Wuwei Pills high-dose group, with 10 rats in each group.

[0075] Animal modeling and drug administration

[0076] After grouping, the experimental cycle was 36 days. Doxorubicin was injected every other day from day 1 to day 11, for a total of 6 times, with a cumulative dose of 15 mg / kg, and the administration method was tail vein injection; trastuzumab was injected every other day from day 19 to day 29, for a total of 6 times, with a cumulative dose of 20 mg / kg, and the administration method was intraperitoneal injection. The treatment group was given the corresponding dose of Roukou Wuwei Pills by gavage, and the total administration time was 36 days. The status of the rats was observed and recorded at any time during the treatment, including: weight change, activity, death, etc.

[0077] Index detection

[0078] After the last administration, the rats in each group were fasted but not watered for 24 hours. After the rats were anesthetized, transthoracic two-dimensional M-mode echocardiography was used to detect the cardiac function of the rats. The main measurement indicators were the left ventricular internal diameter at end-diastole (LVIDd) and the left ventricular internal diameter at end-systole (LVIDs), and the left ventricular ejection fraction (LVEF) and shortening fraction (%FS) parameters were calculated; the rat feces were collected for 16srRNA high-throughput sequencing; the rat serum was collected, and the myocardial injury markers such as cTnI and BNP were detected by kits, and a wide range of targeted metabolic detection was performed; the hearts were dissected, pathological staining was performed, and the pathological changes of the hearts of the rats in each group were observed.

[0079] Experimental Results

[0080] Observation of general condition of rats

[0081] During the drug administration period, the rats in the control group were in good condition, with normal drinking and food intake. The rats in the model group were in poor condition, with decreased appetite, reduced activity, and a large amount of hair loss. The condition of the rats in the Roukou Wuwei Pill group was improved compared with the model group, without a large amount of hair loss or ascites, and the weight loss was slow. No rats died during the drug administration period. The changes in the weight of rats in each group during the drug administration period are shown in Figure 1 .

[0082] Roukou Wuwei Pills alleviate doxorubicin / trastuzumab-related cardiotoxicity

[0083] After treatment, the changes of myocardial injury markers in the blood of rats in each group were shown in Figure 2A -B. Compared with the control group, the cTn I in the model group was significantly increased (P < 0.01); compared with the model group, the cTn I in the high-dose and low-dose groups of Roukou Wuwei Pills were significantly decreased, and the difference was statistically significant (P < 0.05); compared with the control group, the BNP in the model group was significantly increased (P < 0.01); compared with the model group, the BNP in the high-dose and low-dose groups of Roukou Wuwei Pills were significantly decreased, and the difference was statistically significant (P < 0.05).

[0084] After treatment, the changes in cardiac function of rats in each group were shown in Figure 3A -D. Compared with the control group, the LVIDs and LVESV of the model group increased significantly (P < 0.01), and the LVEF and FS decreased significantly (P < 0.01); compared with the model group, the LVIDs and LVESV of the Roukou Wuwei Pill low-dose group decreased significantly (P < 0.01), and the LVEF and FS increased significantly (P < 0.01). M-mode echocardiograms of rats in each group were shown in Figure 4A -D.

[0085] The pathological changes of the heart in each group of rats were as follows Figure 5A -C, the normal group myocardial cells were evenly arranged, with normal morphology and neatly arranged muscle fibers. The model group had myocardial edema, inflammatory cell aggregation, disordered arrangement and even rupture. Compared with the model group, the myocardial cells in the Roukou Wuwei Pill group were more evenly arranged, edema was reduced, and the degree of fiber disorder was reduced. The results showed that Roukou Wuwei Pill improved the myocardial morphological changes caused by doxorubicin / trastuzumab in mice and reduced the pathological damage of myocardial cells.

[0086] Experimental Example 2

[0087] In this example, a low dose of Roukou Wuwei Pills was used to study the effects of Roukou Wuwei Pills on the changes in biometabolism markers in rat plasma.

[0088] method

[0089] The rat modeling was the same as in Example 1. After the administration cycle, the rat plasma samples were collected, thawed, vortexed for 10 seconds, and 50 μL of the samples were transferred to the corresponding numbered centrifuge tubes. 300 μL of 20% acetonitrile methanol internal standard extract was added, vortexed for 3 minutes, and centrifuged at 4°C, 12000 rpm / min for 10 minutes. After centrifugation, the supernatant was transferred and allowed to stand at -20°C for 30 minutes; centrifuged again at 4°C, 12000 rpm / min for 3 minutes, and the supernatant was transferred for analysis on the machine.

[0090] result

[0091] PCA analysis

[0092] PCA score Fig. 6A -B. As shown in the PCA results, under the positive and negative ion modes, the normal group, model group, and Roukou Wuwei Pills group can be well distinguished, indicating that the metabolic profiles of rats in each group are different. In the figure, the model group is farthest from the normal group, indicating that the metabolic profiles of rats in the model group are significantly different from those in the normal group. The Roukou Wuwei Pills group is well distinguished from the model group, indicating that Roukou Wuwei Pills significantly changed the metabolic profiles of the model rats.

[0093] OPLS-DA analysis

[0094] In order to further distinguish the differences in the physiological metabolic environment of rats under different conditions, the supervised pattern recognition method OPLS-DA was used for analysis. Fig. 7A -B shows that in the positive ion mode, the normal group and the model group, and the model group and the Roukou Wuwei Pill group can be clearly distinguished, and are located on both sides of the ordinate, respectively, indicating that the differences between the groups are large. A 200 permutation test was performed to verify the OPLS-DA model. It can be seen that the simulated values ​​are all lower than the original values ​​on the far right, and the regression line intercepts of Q2 are all less than 0.05. The above results show that the model has good fit and prediction ability, and there is no overfitting phenomenon, and the results are reliable.

[0095] Screening of differential metabolites

[0096] Based on the establishment of the OPLS-DA model, the differential metabolites were screened using VIP>1, P<0.05 or FC>1.5 as the criteria. Fig. 8A -B shows that there are 971 differential variables between the normal group and the model group, of which 286 are upregulated and 685 are downregulated; there are 399 differential variables between the model group and the Roukou Wuwei Pill group, of which 186 are upregulated and 213 are downregulated. The intersection of the differential metabolites of the two groups was taken, and there were 210 common differential metabolites, see Fig. 9 .

[0097] Enrichment pathway analysis

[0098] In order to further explore the changes in the metabolic function and metabolic pathways of Roukou Wuwei Pills on doxorubicin / trastuzumab rats, the above 269 differential metabolite data were imported into MetaboAnalyst 6.0 for KEGG enrichment analysis. Fig.10 As shown, with P < 0.05, Impact > 0.1 as the screening criteria, tryptophan metabolism was enriched as the key metabolic pathway, and the key metabolites enriched included indole-3-acetaldehyde, 3-hydroxy-2-aminobenzoic acid, 4-(2-aminophenyl)-2,4-dioxobutanoic acid, and 5-hydroxyindoleacetic acid.

[0099] Metabolites, as the basis of the phenotype of organisms, can serve as an important window to understand various biological processes and mechanisms. Metabolomics has become a powerful tool for discovering cardiovascular biomarkers, early prediction and risk assessment. By exploring the relationship and mechanism between cardiovascular disease and metabolomics and describing the cardiovascular metabolome map, it can provide a basis for early prevention and mechanism research of cardiovascular disease. Tryptophan is an essential amino acid for the human body. It is a core component for the synthesis of various proteins in the human body and a key substrate source for promoting the production of a series of key molecules. Tryptophan can generate various derivatives through the tryptophan-kynurenine metabolic pathway, the tryptophan-indole metabolic pathway, and the tryptophan-5-hydroxytryptamine pathway to exert biological effects. The results of extensive targeted metabolomics indicate that Roukou Wuwei Pills may alleviate doxorubicin / trastuzumab-related cardiotoxicity by regulating tryptophan metabolism.

[0100] Experimental Example 3

[0101] In this example, a low dose of Roukou Wuwei Pills was used to study the effect of Roukou Wuwei Pills on the intestinal flora of rats.

[0102] method

[0103] The rat model was the same as in Example 1. After the administration period, the rat feces were collected and DNA was extracted using the CTAB extraction method in strict accordance with the instructions. Amplification, library construction, sequencing and data processing were then performed.

[0104] result

[0105] α Biodiversity

[0106] Alpha diversity is mainly used to study the community diversity within a habitat (or sample). Sobs, Chao and Ace are indices used to evaluate community richness. The higher the index, the richer the community. Shannon is an index used to reflect community diversity. The higher the index, the more complex the sample diversity. Fig.11 As shown in the figure, compared with the control group, the Sobs, Chao, Ace and Shannon indexes of the model group decreased significantly (P < 0.01); compared with the model group, the Sobs, Chao, Ace and Shannon indexes of the Roukou Wuwei Pill group decreased significantly (P < 0.01). The above results show that doxorubicin / trastuzumab changed the composition of the intestinal flora in normal rats, reducing the diversity and richness of the flora, while Roukou Wuwei Pill can increase the diversity and richness of the intestinal flora in rats.

[0107] β Biodiversity

[0108] β-diversity analysis was performed by comparing the microbial community composition of different samples, including principal component analysis (PCA), principal coordinates analysis (PCoA), non-metric multi-dimensional scaling (NMDS), etc.

[0109] like Fig. 12A -B, the control group, model group and Roukou Wuwei Pills group were well separated under both analyses and were relatively close to the normal group. This result indicated that Roukou Wuwei Pills could change the intestinal flora structure of rats in the model group and make it closer to that of the normal group.

[0110] Roukou Wuwei Pills alters the intestinal flora composition of rats with doxorubicin / trastuzumab-induced cardiotoxicity at the multispecies level

[0111] To investigate the specific changes in the bacterial community, cluster histograms were plotted to show the changes in the intestinal flora within phyla, genera, and subgroups in each sample. Fig.13A -C shows that at the phylum level, Firmicutes, Bacteroidota and Actinobacteriota were dominant phyla in the three groups. Compared with the normal group, the abundance of Firmicutes and Actinobacteria in the model group increased, while the abundance of Firmicutes and Actinobacteria in the Roukou Wuwei Pill group decreased.

[0112] At the family level, doxorubicin followed by trastuzumab reduced the abundance of Lactobacillaceae, Lachnospiraceae, norank_o_Clostridia_UCG-014, and Prevotellaceae, and increased the abundance of Bifidobacteriaceae and Clostridiaceae in rats; whereas administration of Roukou Wuwei Pills increased the abundance of Lachnospiraceae and norank_o_Clostridia_UCG-014, and reduced the abundance of Bifidobacteriaceae and Clostridiaceae in rats.

[0113] At the genus level, doxorubicin followed by trastuzumab increased the abundance of norank_f_Muribaculaceae, Bifidobacterium, Clostridium_sensu_stricto_1, and Faecalibaculum, and decreased the abundance of norank_f_norank_o_Clostridia_UCG-014, norank_f_norank_o_RF39, and Lachnospiraceae_NK4A136_group in rats; whereas Roukou Wuwei Pills administration decreased the abundance of Bifidobacterium, Clostridium_sensu_stricto_1, Faecalibaculum, and norank_f_Erysipelotrichaceae in rats.

[0114] LEfSe analysis

[0115] LEfSe (Linear discriminant analysis Effect Size) can be used to discover the species characteristics that best explain the differences between groups in two or more groups of samples, as well as the extent to which these characteristics affect the differences between groups. In order to determine which bacteria were altered by Roukou Wuwei Pills treatment and thereby alleviate doxorubicin / trastuzumab-induced cardiotoxicity, high-dimensional class comparisons were performed using linear discriminant analysis (LDA) effect size (LEfSe) analysis to find significant differences in the dominance of bacterial communities between the two groups.

[0116] In the model group, Actinobacteria and Bifidobacteriales were relatively enriched; while the Roukou Wuwei Pill group increased the abundance of Norank_f_Norank_o_Clostridia_UCG-014, Clostridia_UCG-014 and Norank_o_Clostridia_UCG-014 ( Fig.14A -B). The above results together emphasize that doxorubicin / trastuzumab significantly alters the diversity and composition of the intestinal microbiota, and Roukou Wuwei Pills may alleviate cardiotoxicity by modulating these changes.

[0117] The above is only an embodiment of the present invention. A person of ordinary skill in the art is aware of all the common technical knowledge in the technical field to which the invention belongs before the filing date or the priority date, is able to obtain all the prior art in the field, and has the ability to apply conventional experimental means before that date. A person of ordinary skill in the field can improve and implement this solution in combination with his own ability under the enlightenment given by this application. It should be pointed out that for a person of ordinary skill in the art, without departing from the structure of the present invention, several deformations and improvements can be made, which should also be regarded as the scope of protection of the present invention, and these will not affect the effect of the implementation of the present invention and the practicality of the patent. The scope of protection claimed in this application shall be based on the content of its claims, and the specific implementation methods and other records in the specification can be used to interpret the content of the claims.

[0118] It should be pointed out that, for those of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. In addition, it should be understood that after reading the above teaching content of the present invention, those skilled in the art can make various changes or modifications to the present invention, and the equivalent forms obtained also fall within the protection scope of the present application. It should also be understood that the technical solutions obtained by those skilled in the art through logical analysis, reasoning or limited experiments on the basis of the technical solutions provided by the present invention are all within the protection scope of the claims attached to the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the content of the attached claims, and the description and drawings can be used to interpret the content of the claims.

Claims

1. Application of Roukou Wuwei Pills in the preparation of drugs for alleviating anthracycline chemotherapy drugs and tumor molecular targeted drugs-related cardiotoxicity.

2. The use according to claim 1, wherein the anthracycline chemotherapy drug tumor molecular targeted drug is doxorubicin and trastuzumab.

3. The use according to claim 1 or 2, wherein the cardiac toxicity includes decreased left ventricular ejection fraction and left ventricular shortening fraction, increased left ventricular end-systolic volume and left ventricular end-systolic diameter, increased serum cTnI and BNP levels, and pathological damage to cardiac tissue.

4. The use according to claim 1 or 2, wherein: The drug has one or more of the following functions: (1) Increase left ventricular ejection fraction and left ventricular fractional shortening; (2) decreased left ventricular end-systolic volume and increased left ventricular end-systolic diameter; (4) Reduce serum cTnI and BNP levels; (3) Improve cardiac tissue pathological damage.

5. Application of Roukou Wuwei Pills in the preparation of drugs for alleviating intestinal microbial imbalance caused by anthracycline chemotherapy drugs and tumor molecular targeted drugs.

6. The use according to claim 5, wherein the light anthracycline chemotherapy drug tumor molecular targeted drug is doxorubicin and trastuzumab.

7. The use according to claim 5 or 6, wherein the intestinal microbial imbalance includes an increase in the abundance of Firmicutes and Actinobacteria; a decrease in the abundance of Lactobacillaceae, Lachnospiraceae, norank_o_Clostridia_UCG-014, and Prevotellaceae; an increase in the abundance of Bifidobacteriaceae and Clostridiumaceae; an increase in the abundance of norank_f_Muribaculaceae, Bifidobacterium, Clostridium_sensu_stricto_1, and Faecalibacterium; and a decrease in the abundance of orank_f_norank_o_Clostridia_UCG-014, norank_f_norank_o_RF39, and Lachnospiraceae_NK4A136_group.

8. The use according to any one of claims 5 to 7, wherein the drug has one or more of the following functions: (1) Reduce the abundance of Firmicutes and Actinobacteria; (2) increased abundance of Lactobacillusaceae, Lachnospiraceae, norank_o_Clostridia_UCG-014, and Prevotellaceae in rats; (3) reduce the abundance of Bifidobacteriaceae and Clostridiaceae; (4) reduced abundance of norank_f_Muribaculaceae, Bifidobacterium, Clostridium_sensu_stricto_1, and Faecalibacterium; (5) The abundance of norank_f_norank_o_Clostridia_UCG-014, norank_f_norank_o_RF39, and Lachnospiraceae_NK4A136_group increased.

9. The application of Roukou Wuwei Pills in the preparation of drugs for alleviating metabolic disorders caused by anthracycline chemotherapy drugs and tumor molecular targeted drugs.

10. The use according to claim 9, wherein the anthracycline chemotherapeutic tumor molecular targeted drugs are doxorubicin and trastuzumab.

11. The use according to claim 10, wherein the drug regulates the level of tryptophan metabolites.

12. The use according to any one of claims 1 to 11, wherein the drug is for oral administration.

13. The use according to claim 13, wherein the medicine comprises pharmaceutically acceptable excipients.

14. The use according to claims 1-13, wherein the Roukou Wuwei Pills are prepared from nutmeg, inulin, costusroot, jujube and piper longum.

15. The use according to claims 1-14, wherein the anthracycline chemotherapeutic drug tumor molecular targeted drug is an anti-breast cancer drug.

Citation Information

Patent Citations

  • Traditional Chinese medicine concentrated pill for treating targeted drug related cardiotoxicity as well as preparation and application of traditional Chinese medicine concentrated pill

    CN117224603A